Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27914428 | 0.95 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL27914441 | 0.95 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL27896900 | 0.91 | HIF1A (0.62) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL13244556 | 0.82 | HRH3 (0.56) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL155961 | 0.82 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL578590 | 0.82 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL15904021 | 0.82 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL27896937 | 0.81 | SIGMAR1 (0.54) | HRH3KCNJ1AOC3 | |
| SCHEMBL27914458 | 0.81 | HRH3 (0.59) | HRH3ALDH1A1HPGDMMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | claimed |
| CN-1093701-A | Antiretroviral hydrazine derivative | CIBA GEIGY AG (CH) | 1994-10-19 | — | — | CN | claimed |
| CN-1089606-A | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1994-07-20 | — | — | CN | claimed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-1858898-B1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1858898-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006092510-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-08 | — | — | WO | disclosed |
| US-20050222098-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
| CN-1089606-A | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1994-07-20 | — | — | CN | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222098-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | HRH3 3595/4885SMN1; SMN2 2427/4885ALDH1A1 2659/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | HRH3 3595/4885SMN1; SMN2 2427/4885ALDH1A1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.